Johnson & Johnson has been jockeying to snap up Actelion, Europe's largest biotech and a maker of
drugs for the deadly heart and lung condition pulmonary
arterial hypertension (PAH).
The company's lead candidate is Trevyent, a development stage
drug product that utilizes SteadyMed's PatchPump technology to administer treprostinil, a vasodilatory prostacyclin analogue to treat pulmonary
arterial hypertension.
United Therapeutics will pay $ 4.46 per share in cash at closing yesterday and an additional $ 2.63 per share in cash upon the achievement of a milestone related to the commercialization of SteadyMed's leading
drug candidate Trevyent for the treatment of Pulmonary
Arterial Hypertension (PAH).
Edward Bullmore, UK Robert Dow, UK Garrett Fitzgerald, USA - Prostanoid biology and the role of peripheral molecular clocks in cardiovascular biology, metabolism and aging Alex Phipps, UK - Oncology, Clinical Pharmacology, Biologics and Immunotherapy Patrick du Souich, Canada - Cytochrome P450, membrane carriers, disease, inflammation, rational use of
drugs, clinical pharmacology David J. Webb, UK -
hypertension, chronic kidney disease, endothelial function and dysfunction,
arterial stiffness, health technology assessment, medicines regulation Don Birkett, Australia - Clinical pharmacology / pharmacokinetics and
drug utilisation